Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BZT-003
- Development stage
- Preclinical
- Lead developer
- Biomatz
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
BZT-003 is a topical live biotherapeutic product (LBP) candidate developed by Biomatz for the treatment of atopic dermatitis. It is a defined two-strain microbial consortium consisting of *Streptococcus salivarius* BZ3947 and *Leuconostoc mesenteroides* BZ1505. Designed using Biomatz's BASyMCo (Bespoke Assembly of a Synthetic Microbial Consortium) platform, BZT-003 targets the core pathological axes of atopic dermatitis by selectively suppressing *Staphylococcus aureus* colonization while preserving beneficial skin commensals. Additionally, BZT-003 promotes epidermal barrier restoration by upregulating ceramide synthesis in keratinocytes and attenuates inflammatory signaling by suppressing pro-inflammatory cytokines (such as TNF-α, IL-6, and IL-1β) and Th2-associated chemokines (including TARC, MDC, and RANTES).
- Other names
- Streptococcus salivarius BZ3947 + Leuconostoc mesenteroides BZ1505Streptococcus salivarius BZ3947 and Leuconostoc mesenteroides BZ1505
02
Targets
CCL17 (C-C motif chemokine ligand 17)CCL22 (C-C motif chemokine ligand 22)CCL5 (C-C Motif Chemokine Ligand 5)IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)NOS2 (Nitric Oxide Synthase 2)
Beyond the preview
Go deeper on BZT-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BZT-003.